smartcybers786@gmail.com 
A DNA double helix is seen in an undated artist's illustration. — Reuters
#Pakistani #girl #cured #thalassemia #China
According to the Chinese daily, a four -year -old Pakistani girl diagnosed with severe thalassemia has been successfully treated with Chinese -developed genes editing medicines, which is allegedly used by the first use of this technology on a foreign minor.
The girl, whose name is Isa, relied on regular blood transfusion to survive. According to hospital officials, his condition has improved significantly after receiving treatment earlier this year, which ended his dependence on his transfer and allowed him to return to normal life.
A small event was held on Tuesday to celebrate its recovery.
Eiza was brought by her parents in January to undergo experienced genes editing therapy known as CS-101, a base editing drug developed to treat severe beta thalassemia.
The treatment is part of the Clinical Research Initiative, which was launched in 2023, headed by Professor Xi Xiaon in collaboration with Shanghai -based biotechnology firm, in collaboration with the correct order treatment.
The hospital reports that a total of four patients, including AIZA, have received therapy so far, the results of the results of safety and utility.
“With the complex care of the hospital’s multi -sophisticated team of the hospital, the baby’s total hemoglobin concentration has exceeded 100 grams per liter, causing him to get rid of blood transfer successfully,” said Dr. Kayan Xiaoon. “The whole treatment process easily developed.”
Doctors noted that patients with severe thalassemia usually need a monthly transfer to their lives and if they are not treated, they face life -threatening complications.
A 40 -year -old physicist in Hong Kong and former Post Documentary researcher, Ezra’s father, Mohammad Adeel, thanked the medical team for flowers and thanks to your family during the ceremony.
He said the family faced both extraordinary medical care and emotional support throughout the treatment process. Adeel added that during his recovery, the second of his three children, Aisa, faced emotional fluctuations, but health care workers helped them.
While working in Hong Kong, Adeel started searching for a constant treatment with his daughter. In April last year, it discovered online that CS-101 therapy has shown success in other pediatric patients and reached the company for treatment.
As part of this procedure, doctors collected Aiza’s Atologas hematoputic stem cells, applied CS-101 drugs to clearly edit specific genetic goals, and reuse its body-modified cells.
The amendments reinstated the necessary protein expression and restored the function carrying the oxygen of hemoglobin. As a result, the level of hemoglobin increased to a healthy individual, which eliminated the need for further transition.
At a Tuesday ceremony, the hospital presented Eiza with gifts and wished her constant health and happiness.
The correct section treatment also gave a card gift that it was written: “I wish your life was filled with prosperity and happiness. Your smile and love will illuminate more lives in the world.”
Thalassemia is an inherited bloodshed that has a high proliferation in the Mediterranean basin, the Middle East, Africa, Southeast Asia, and southern China.
“This success will help accelerate the clinical translation of technology that amended China’s original gene,” said Professor Xi, who also worked as the vice president of the hospital. “This offers hope for a timely treatment for patients around the world.
Xi added that hospitals and proper sequences are looking for the use of the same technology to treat children suffering from other genetic metabolic disorders.
